Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 10, 2002, Pages 1701-1708

  Tougas, G ^a   Snape Jr , W J ^b   Otten, M H ^c   Earnest, D L ^d   Langaker, K E ^e   Pruitt, R E ^f   Pecher, E ^d   Nault, B ^d   Rojavin, M A ^d  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b Medical Center ^*  (United States)

^c EEMLAND HOSPITAL   (Netherlands)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Medical Clinic   (Norway)

^f St Thomas Medical Plaza West ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 4 AGONIST; TEGASEROD;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; GASTROINTESTINAL MOTILITY; HEADACHE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; COLONIC DISEASES, FUNCTIONAL; CONSTIPATION; DIARRHEA; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; MALE; MIDDLE AGED; PATIENT DROPOUTS; SEROTONIN AGONISTS;

EID: 0036792345     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01347.x     Document Type: Article

References (23)

1. Farthing MJ. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Baillieres Clin Gastroenterol 1999; 13: 461-71.
2. Lee OY, Schmulson M, Mayer EA. Common functional gastrointestinal disorders: nonulcer dyspepsia and irritable bowel syndrome. Clin Cornerstone 1999; 1: 57-71.
3. Wald A. Irritable bowel syndrome. Curr Treat Options Gastroenterol 1999; 2: 13-9.
4. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48: 14-9.
5. Camilleri M. Tegaserod. Aliment Pharmacol Ther 2001; 15: 277-89.
6. Scott LJ. Perry CM. Tegaserod. Drugs 1999; 58: 491-6.
7. Scarpignato C, Pelosini I. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Can J Gastroenterol 1999; 13(Suppl. A): 50A-65A.
8. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
9. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
10. Northcutt AR, Mangel AW, Hamm LR, et al. Persistent placebo response during a year-long controlled trial of IBS treatment. Gastroenterology 2001; 120(Suppl. 1): 3243(Abstract).
11. Drossman DA, Thompson W, Talley NJ, et al. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int 1990; 3: 159-72.
12. Drossman DA, Richter J, Talley NJ, et al. The Functional Gastrointestinal Disorders. 1st edn. McLean, VA: Degnon Associates, 1994.
13. Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-11.
14. Ruigomez A, Wallander MA, Johansson S, Garcia Rodriguez LA. One-year follow-up of newly diagnosed irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1097-102.
15. Dobrilla G, Imbimbo BP. Piazzi L. Bensi G. Long-term treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut 1990; 31: 355-8.
16. Gilbody JS, Fletcher CP, Hughes IW. Kidman SP. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract 2000; 54: 461-4.
17. Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1419-27.
18. Noor N, Small PK, Loudon MA, et al. Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome. Scand J Gastroenterol 1998; 33: 605-11.
19. Centonze V, Imbimbo BP, Campanozzi F, et al. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol 1988; 83: 1262-6.
20. Mathias JR. Clench MH, Roberts PH, Reeves-Darby VG. Effect of leuprolide acetate in patients with functional bowel disease. Long-term follow-up after double-blind, placebo-controlled study. Dig Dis Sci 1994; 39: 1163-70.
21. Benatar A. Feenstra A, Decraene T, Vandenplas Y. Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography. Pediatrics 2000; 106: E85.
22. Drici MD, Ebert SN, Wang WX, et al. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart, J Cardiovasc Pharmacol 1999; 34: 82-8.
23. Drolet B, Khalifa M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97: 204-10.